Study confirms long-lasting benefit of radiotherapy for localized breast cancer, and reports importance of tamoxifen for reducing recurrence

December 07, 2010

Women with the most common type of non-invasive breast cancer known as ductal carcinoma in situ (DCIS) are significantly less likely to develop invasive disease if they are given radiotherapy after surgery, and the effect is long lasting, according to the long-term results of the UK, Australia, and New Zealand (UK/ANZ) DCIS trial, published Online First in The Lancet Oncology. Moreover, treatment with tamoxifen significantly reduces the likelihood of local cancer coming back after surgery.

DCIS refers to cancer in the milk ducts of the breast, and now represents around 20󈞅% of screen detected breast cancers. The introduction of the UK National Health Service Breast Screening Programme has led to a substantial increase in the diagnosis of DCIS over the past two decades. Standard treatments after breast-conserving surgery include radiotherapy and hormone therapy. Survival following treatment is about 98%, but the risk of local recurrence and a new cancer in the opposite breast is high.

The UK/ANZ DCIS trial was designed to establish whether additional treatment with tamoxifen, or radiotherapy, or both tamoxifen and radiotherapy could reduce the likelihood of cancer coming back after surgery to completely remove DCIS. Between May 1990 and August 1998, 1701 women from the UK, Australia, and New Zealand were enrolled.

In 2003, initial results (median follow-up 4.4 years) suggested that radiotherapy reduced new invasive and local recurrences by about half, but no significant effects were noted with tamoxifen treatment.

In this study, Jack Cuzick from Cancer Research UK and Queen Mary's School of Medicine and Dentistry, London, UK, and colleagues report the long-term follow-up (median 12.7 years) of women from the UK/ANZ DCIS trial.

Radiotherapy after surgery reduced the relative risk of new invasive cancer in the same breast by almost 70% and decreased recurrent DCIS in the same breast by over 60%, corresponding to an absolute 10-year reduction in local cancer recurrences of 12.3%. Treatment with radiotherapy had no effect on cancer risk in the other breast.

Treatment with tamoxifen significantly reduced all new breast events, corresponding to an absolute 10-year reduction of 6.5%. Tamoxifen lowered the relative risk of recurrence in the same breast by around 30% (an absolute 10-year reduction of 3.9%) and decreased the risk of new cancer in the other breast by over 65% (an absolute 10-year reduction of 2.3%). However, tamoxifen had no effect on invasive cancer in the same breast as the initial DCIS, and seemed to have no added benefit in patients who were given radiotherapy.

The authors say: "This updated analysis confirms the long-term beneficial effect of radiotherapy and reports a benefit for tamoxifen in reducing local and contralateral new breast events for women with DCIS treated by complete local excision."

They conclude: "This trial emphasises the importance of radiotherapy in high-grade [more quickly growing and more likely to spread] DCIS and also suggests a role for tamoxifen primarily for new contralateral disease."

In a Comment, Henry Mark Kuerer from the University of Texas MD Anderson Cancer Center, Houston, USA, says: "The message for readers and our patients is that we are over-treating many cases of small, mammographically detected DCIS."

He adds: "Our focus now should be accurate molecular identification of patients with DCIS who can safely forego any therapy because their risk of developing potentially life-threatening invasive carcinoma is little to none."
-end-
Professor Jack Cuzick, Cancer Research UK and Queen Mary's School of Medicine and Dentistry, University of London, London, UK. Please note Professor Cuzick is currently in the USA 7 hrs behind the UK. T) +44 (0)7785 542 166 E) j.cuzick@qmul.ac.uk

Dr Henry Mark Kuerer, University of Texas MD Anderson Cancer Center, Houston, USA. T) +1 713 745 5043 E) hkuerer@mdanderson.org

For full Article and Comment, see: http://press.thelancet.com/tloukanz.pdf

NOTE: THE ABOVE LINK IS FOR JOURNALISTS ONLY; IF YOU WISH TO PROVIDE A LINK TO THE FREE ABSTRACT OF THIS PAPER FOR YOUR READERS, PLEASE USE THE FOLLOWING, WHICH WILL GO LIVE AT THE TIME THE EMBARGO LIFTS: http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70266-7/abstract

Lancet

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.